NCT07085676 - Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2030

Conditions

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)Rheumatoid Arthritis (RA)

Interventions

BIOLOGICAL

HBI0101 CART

HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.

Trial Locations (1)

9574869

RECRUITING

Hadassah MO, Jerusalem

All Listed Sponsors

lead

Polina Stepensky

OTHER